- Home
- / CSL Behring
CSL Behring
Revenue
$7.9 B
FY, 2020
CSL Behring Summary
Company Summary
- Overview
- CSL Behring is a provider of life-saving medicines. It develops and delivers a range of medicines to treat disorders such as haemophilia and primary immune deficiencies, and vaccines to prevent influenza. CSL Behring's therapies are also used in cardiac surgery, organ transplantation, and burn treatment.
- Type
- Subsidiary
- Status
- Active
- Founded
- 1904
- HQ
- King of Prussia, PA, US | view all locations
- Website
- http://www.cslbehring.com/
- Cybersecurity rating
Table of Contents
Key People
Bill Campbell, Executive Vice President and Chief Commercial Officer
Paul McKenzie, Chief Operating Officer
Greg Boss, Executive Vice President Legal and CSL Limited Group General Counsel
Operating MetricsView all
Plasma Collection Centers
275
Sep, 2020
Patent Applications
3
Dec, 2020
Trademarks
4
Dec, 2020
LocationsView all
37 locations detected
King of Prussia, PA HQ
United States
1020 1st Ave
Bradley, IL
United States
1201 N Kinzie Ave
Kankakee, IL
United States
P.O. Box 511
Broadmeadows, VIC
Australia
209 Camp Rd
Parkville, VIC
Australia
45 Poplar Rd
Parkville, VIC
Australia
Unit 400/30 Flemington Rd
CSL Behring Financials
Summary Financials
- Revenue (FY, 2020)
- $7.9B
- Gross profit (FY, 2020)
- $4.5B
- EBIT (FY, 2020)
- $2.5B